Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura

Wang,Jiuhe; Wang,Bin; Sun,Zhonghui; Xue,Kezeng

doi:10.3892/etm.2019.7196

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura

Authors:
- Jiuhe Wang
- Bin Wang
- Zhonghui Sun
- Kezeng Xue
View Affiliations

Affiliations: Department of Hematology, Qingdao Hiser Medical Group, Qingdao, Shandong 266000, P.R. China, Ward Pharmacy, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China, Department of Pharmacy, The Eighth People's Hospital of Qingdao, Qingdao, Shandong 266000, P.R. China
Published online on: January 23, 2019 https://doi.org/10.3892/etm.2019.7196
Pages: 2137-2142
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura (ITP) were investigated. We retrospectively analyzed 249 patients with refractory ITP who were admitted to Qingdao Hiser Medical Group between March 2013 and March 2017. Curative effects of patients treated with rituximab, cyclophosphamide, and combination therapy were observed and the changes of platelet count, PA IgG, and lymphocyte CD20 before and after treatment, as well as the incidence of adverse reactions after treatment, were compared. There was no significant difference in the expression of lymphocyte CD20, PA IgG and platelet count among the three groups of refractory ITP patients before treatment (P>0.05). After treatment, the expression levels of CD20 and PA IgG in lymphocytes were significantly downregulated, and platelet counts significantly increased in the three groups (P<0.05). After treatment, CD20 and PA IgG levels in combined therapy group were significantly lower, and platelet count was significantly higher, than those in the rituximab and cyclophosphamide groups (P<0.05). Also, after rituximab treatment, the expression levels of CD20 and PA IgG in lymphocytes were significantly lower than those in cyclophosphamide group (P<0.05), and platelet count was higher than that in cyclophosphamide group (P<0.05). After treatment, the total effective rate in combined therapy group was higher than that in the rituximab and cyclophosphamide group (P<0.05). Total effective rate of rituximab group was significantly higher than that of cyclophosphamide group (P<0.05). The incidence of adverse reactions in combined therapy group was 14.29% (12/84), which was significantly lower than that in cyclophosphamide group (40.70%, 35/86, P<0.05) and rituximab group (29.11%, 23/79, P<0.05). The application of rituximab combined with cyclophosphamide in the treatment of refractory ITP can improve patient's clinical symptoms. The efficacy of this technique is promising with no serious adverse reactions. This technique should be popularized in clinical practice.

View Figures

View References

1	Oved JH, Lee CS and Bussel JB: Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone. J Pediatr. 191:225–231. 2017. View Article : Google Scholar : PubMed/NCBI
2	Takase K, Kada A, Iwasaki H, Yoshida I, Sawamura M, Yoshio N, Yoshida S, Iida H, Otsuka M, Takafuta T, et al: High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: Protocol for a multicenter, open-label, single arm trial. Acta Med Okayama. 72:197–201. 2018.PubMed/NCBI
3	Zhao CH and Hou M: Advances of research on abnormality of cell immunity in idiopathic thrombocytopenic purpura: Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 14:1045–1048. 2006.(In Chinese). PubMed/NCBI
4	Chandan JS, Thomas T, Lee S, Marshall T, Willis B, Nirantharakumar K and Gill P: The association between idiopathic thrombocytopenic purpura and cardiovascular disease: A retrospective cohort study. J Thromb Haemost. 16:474–480. 2018. View Article : Google Scholar : PubMed/NCBI
5	Wasserman RL: Gammaplex^® 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. Immunotherapy. 9:1071–1088. 2017. View Article : Google Scholar : PubMed/NCBI
6	Niscola P, Scaramucci L and Giovannini M: Spleen tyrosine kinase inhibition: A new promising approach to chronic and refractory immune thrombocytopenia. Immunotherapy. 10:5–7. 2018. View Article : Google Scholar : PubMed/NCBI
7	Vendramin C, Thomas M, Westwood JP, McGuckin S and Scully M: Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: The role of anti-rituximab antibodies. Br J Haematol. Mar 12–2018.(Epub ahead of print). doi: 10.1111/bjh.15177. View Article : Google Scholar
8	Martinez AR, Paul MR and Kuo DJ: Treatment of immune thrombocytopenic purpura associated with cytomegalovirus infection in a child with pre-B cell acute lymphoblastic leukaemia after central nervous system relapse. BMJ Case Rep. 2017(pii): bcr-2017-221947. 2017.
9	Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK and George JN: Thrombotic thrombocytopenic purpura: Diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 1:590–600. 2017. View Article : Google Scholar : PubMed/NCBI
10	Molineux G and Newland A: Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: From bench to bedside. Br J Haematol. 150:9–20. 2010.PubMed/NCBI
11	Chowdhry M, Makroo RN, Thakur Y, Agrawal S, Mishra M and Rani D: Hyperheptaploidy in idiopathic thrombocytopenic purpura. Indian J Pathol Microbiol. 61:161–162. 2018. View Article : Google Scholar : PubMed/NCBI
12	Kubota M, Usami I, Kobayashi K, Tsutsui T and Matsubara K: Serum immunoglobulin levels at onset: Association with the prognosis of childhood idiopathic thrombocytopenic purpura. Int J Hematol. 77:304–307. 2003. View Article : Google Scholar : PubMed/NCBI
13	Raheja H, Kumar V, Hollander G, Shani J and Greenberg Y: Intravenous immunoglobulin-induced profound bradycardia in a patient with idiopathic thrombocytopenic purpura. Am J Ther. 25:e572–e574. 2018.PubMed/NCBI
14	Rezaeeyan H, Jaseb K, Alghasi A, Asnafi AA and Saki N: Association between gene polymorphisms and clinical features in idiopathic thrombocytopenic purpura patients. Blood Coagul Fibrinolysis. 28:617–622. 2017. View Article : Google Scholar : PubMed/NCBI
15	Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H and Zeldin RK: Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 15:1448–1452. 2017. View Article : Google Scholar : PubMed/NCBI
16	Payandeh M, Sohrabi N, Zare ME, Kansestani AN and Hashemian AH: Platelet count response to Helicobacter pylori eradication in Iranian patients with idiopathic thrombocytopenic purpura. Mediterr J Hematol Infect Dis. 4:e20120562012. View Article : Google Scholar : PubMed/NCBI
17	Shoukat BA, Ali O, Kumar D, Bilal Gilani M, Zahid A, Aslam Joiya S and Anwar Malik M: Hypogammaglobulinemia observed one year after rituximab treatment for idiopathic thrombocytopenic purpura. Case Rep Med. 2018:20961862018. View Article : Google Scholar : PubMed/NCBI
18	Warner NC, Vaughan LB and Wenzel RP: Human immunodeficiency virus associated thrombotic thrombocytopenic purpura, a clinical conundrum. J Clin Apher. 32:567–570. 2017. View Article : Google Scholar : PubMed/NCBI
19	Gödel P, Fischer J, Scheid C, Gathof BS, Wolf J and Rybniker J: Familial acquired thrombotic thrombocytopenic purpura in siblings - no immunogenetic link with associated human leucocyte antigens. Eur J Haematol. 98:311–313. 2017. View Article : Google Scholar : PubMed/NCBI
20	Rashid RM, Nabi Z, Ansari AZ and Qaiser QA: Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy. BMC Nephrol. 19:692018. View Article : Google Scholar : PubMed/NCBI
21	Duperier T, Brody F, Felsher J, Walsh RM, Rosen M and Ponsky J: Predictive factors for successful laparoscopic splenectomy in patients with immune thrombocytopenic purpura. Arch Surg. 139:61–66. 2004. View Article : Google Scholar : PubMed/NCBI
22	Al Askar AS, Shaheen NA, Al Zahrani M, Al Otaibi MG, Al Qahtani BS, Ahmed F, Al Zughaibi M, Kamran I, Mendoza MA and Khan A: Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: A single center experience. Int J Hematol. 107:69–74. 2018. View Article : Google Scholar : PubMed/NCBI